Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-
about
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studiesInterdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancerEndothelinSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Targeting the adaptive molecular landscape of castration-resistant prostate cancerDocetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialPertussis toxin, an inhibitor of G(αi) PCR, inhibits bile acid- and cytokine-induced apoptosis in primary rat hepatocytesRecent advances in bone-targeted therapies of metastatic prostate cancerBone-targeting agents in prostate cancer.Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.Emerging therapies in metastatic bone pain.Targeted therapy in prostate cancer.Role of the endothelin axis and its antagonists in the treatment of cancerA Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.Castration-resistant prostate cancer: mechanisms, targets, and treatment.Emerging targeted therapies for castration-resistant prostate cancer.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures."New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyEndothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cellsTherapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Emerging therapies to prevent skeletal morbidity in men with prostate cancer.The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Endothelins and their receptors in cancer: identification of therapeutic targets.Current treatment strategies for castration-resistant prostate cancerBone metastasis in prostate cancer: emerging therapeutic strategies.The changing therapeutic landscape of castration-resistant prostate cancer.Targeting the endothelin axis in prostate carcinoma.Novel targets for VEGF-independent anti-angiogenic drugs.Drug development and clinical trials--the path to an approved cancer drug.Progress in the treatment of bone metastases in cancer patients.Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerImmunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer.Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics.Expression of nociceptive ligands in canine osteosarcoma.Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.Castration-resistant prostate cancer: targeted therapies and individualized treatment
P2860
Q21254636-8F4AB536-4B4B-4F07-BFE4-BD10BCF78953Q24630999-A9B35300-FAF3-4213-A303-C71ECDAE8116Q26767156-B5B18645-A04D-4784-A00E-D80EFE866FC8Q26852544-FB90D744-4E22-4EE9-ACB1-B5C80598E0CDQ27022821-825BB235-0592-4E98-89A8-9C1329C77301Q28294857-659B33B4-538F-4E2D-85B7-3317F0D22C93Q28482165-23DE19FB-CDAE-4E7E-85AA-04C96C5DE542Q33703763-E1E4A58D-92E3-4906-8641-D319D1C06FFAQ33864723-B0D705E9-E937-4CD1-AD75-EE499BAF58ADQ34161050-FEE7086E-F30A-40D5-924C-4E49ED986F6CQ34182919-84A4C469-A361-42CB-A686-5EE913E9ADE6Q34634763-01557EB7-BE22-4E7C-95A1-F5A67666A0EBQ34919570-17D20F44-B27F-4394-97CC-919E09728892Q35698539-C8687E4C-ECBC-45E6-AC75-48C531FEB81BQ35864027-25C8F2BF-5D93-4960-ABDB-98131FB93B22Q35999255-375A480A-F41C-43DC-B778-D95F264B8EA5Q36181578-7B7EAC3B-A44D-4718-BDA2-D2214DA46D1BQ36361371-0BCDDFF3-4EF9-4146-8A4F-CD9179691D3EQ36608738-E5AD835D-2C0A-4565-A522-BA57E2FE186BQ36840731-28443DB5-D4DA-47D7-BD02-AF3AEDB7D2DFQ36910469-4EB2D661-9D5F-4959-834A-F888CAFCB993Q37615017-55593F82-D6C6-46FF-B85C-3FB54DD66F5EQ37641292-8B6E14D1-8D46-4198-B42C-F1BF943790E4Q37720488-31B6DE2F-3D52-47B9-A51D-71A3C4C5F953Q37830914-323A2BF7-5806-4B6B-AAFB-9C6827B242B0Q37860950-1CF40F4F-9AF1-4064-98E6-C6F792B23C4CQ37873719-F9C4F5CF-2DB4-465F-BBEA-964D912B4C7AQ37913983-19D56858-432A-47A2-A62B-446A20176450Q37971873-C8E02DA0-FC54-42E4-AD37-FFF978CC9B7FQ37984612-46603595-34EE-4075-8CFA-299FFD804DD2Q37988792-CAF677AE-88B6-479E-A905-5F098D75A0F6Q38002450-9710DBC0-0C48-450C-A856-F5B2D436225EQ38009942-680CBF86-A1B8-408D-9B40-B88D06BFCE8EQ38090562-A8896C0A-9F68-43CB-9EA7-78C85D1E4FC7Q38116358-4C47B0C0-1555-467C-9C9E-4CE61458056CQ38252425-F3EBB9C5-23B5-4D8D-8B04-800FA099BC13Q38263353-D2BF57D0-2A0C-4467-8E54-31C41A4C6F58Q38921965-236CA0FA-5206-496D-B635-B550660A377DQ39106330-ED4202E2-C2E1-45ED-9534-6F5A0CE124BEQ39511732-2FFD1B24-14F1-4DC2-80D7-5A883B9B3E42
P2860
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Final safety and efficacy anal ...... ymptomatic for pain: a double-
@en
Final safety and efficacy anal ...... receptor antagonist zibotentan
@nl
type
label
Final safety and efficacy anal ...... ymptomatic for pain: a double-
@en
Final safety and efficacy anal ...... receptor antagonist zibotentan
@nl
prefLabel
Final safety and efficacy anal ...... ymptomatic for pain: a double-
@en
Final safety and efficacy anal ...... receptor antagonist zibotentan
@nl
P2093
P1433
P1476
Final safety and efficacy anal ...... ymptomatic for pain: a double-
@en
P2093
Armelle Caty
Bernard A Zonnenberg
Heather Payne
Michael Borre
Nancy A Dawson
Nicholas D James
Philippe Beuzeboc
Stuart McIntosh
Thomas Morris
P304
P356
10.1111/J.1464-410X.2010.09638.X
P577
2010-10-01T00:00:00Z